AWM
HRMY icon

AE Wealth Management’s Harmony Biosciences HRMY Stock Holding History

AE Wealth Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,487
Closed -$510K – 2009
2023
Q2 		$510K Buy
+14,487
New +$500K ﹤0.01% 1385

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

AE Wealth Management's HRMY Position: Q3 2023 in Review

AE Wealth Management sold out of Harmony Biosciences (HRMY) in Q3 2023, closing a stake of 14,487 shares — an estimated $510K sold.

AE Wealth Management first reported a position in HRMY in Q2 2023 and held it in 1 quarter. The position peaked at $510K in Q2 2023. 204 funds tracked by Wall St. Rank hold HRMY as of Q3 2023.

  • AE Wealth Management reported no remaining Harmony Biosciences position as of Q3 2023 after selling out during the quarter.
  • AE Wealth Management sold 14,487 Harmony Biosciences shares in Q3 2023, an estimated $510K.
  • AE Wealth Management first reported a position in Harmony Biosciences in Q2 2023 and held it in 1 quarter.
  • AE Wealth Management's Harmony Biosciences position peaked at $510K in Q2 2023.
  • 204 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2023.

Based on AE Wealth Management's 13F filing for Q3 2023, filed 11 Oct 2023.